Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085813 · ClinicalTrials.gov registry record · Phase 2
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT00085813 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT00085813, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously (IV), repeated once every 21 days. A patient may continue treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment.
Conditions Studied
Interventions
- DRUG Ispinesib
Study Locations (11)
Other
- GSK Investigational Site - Brussels
- GSK Investigational Site - Edegem
- GSK Investigational Site - Leuven
Arizona
- GSK Investigational Site - Scottsdale
Florida
- GSK Investigational Site - Jacksonville
Minnesota
- GSK Investigational Site - Rochester
New York
- GSK Investigational Site - Rochester
North Carolina
- GSK Investigational Site - Greensboro
Pennsylvania
- GSK Investigational Site - Philadelphia
Tennessee
- GSK Investigational Site - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085813
The ClinicalTrials.gov registry entry for NCT00085813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ispinesib is the first listed.
NCT00085813 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT00085813 about?
NCT00085813 is a clinical study titled "Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer". This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously ...
What is the current status of trial NCT00085813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2003-12. Estimated completion is 2005-10.
What conditions does trial NCT00085813 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00085813?
The interventions under investigation include: Ispinesib (DRUG).
Who is sponsoring clinical trial NCT00085813?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085813 being conducted?
This trial has 11 study locations across Arizona, Florida, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.